A. Schapira

发表

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

T. Foltynie, J. Cooper, A. McNeill, 2014, Brain : a journal of neurology.

Chaperone-mediated autophagy markers in Parkinson disease brains.

I. Ferrer, J. Obeso, M. Rodriguez-Oroz, 2010, Archives of neurology.

The PINK1—Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells

H. Morris, J. Taanman, A. Schapira, 2021, PloS one.

A randomized, double‐blind, placebo‐controlled trial of safinamide as add‐on therapy in early Parkinson's disease patients

M. Onofrj, F. Stocchi, R. Borgohain, 2012, Movement disorders : official journal of the Movement Disorder Society.

Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors

J. Cooper, K. Chau, A. Schapira, 2009, Journal of the Neurological Sciences.

LETTERS TO THE EDITOR

A. Schapira, G. Fénelon, D. D. Di Monte, 1959, Public Health Nutrition.

Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing

Jean-François Dartigues, Günther Deuschl, Yoav Ben-Shlomo, 2017, Genome Biology.

Mitochondrial function in Parkinson's disease

C. Marsden, J. Cooper, A. Schapira, 1992 .

Quantitation of a mitochondrial DNA deletion in Parkinson's disease

J. Cooper, A. Schapira, Vincent M. Mann, 1992, FEBS letters.

Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson’s disease pathogenesis

J. Cooper, K. Chau, A. Schapira, 2009, Journal of neurochemistry.

Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine

J. Lanciego, R. Cilia, A. Schapira, 2019, Movement disorders : official journal of the Movement Disorder Society.

The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines

K. Chau, M. Gegg, A. Schapira, 2022, bioRxiv.

Inclusion formation in Huntington's disease R6/2 mouse muscle cultures

J. Cooper, M. Orth, G. Bates, 2003, Journal of neurochemistry.

Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon

A. Schapira, M. Steiger, J. McLaughlin, 1993, Annals of neurology.

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease

A. Schapira, E. Menozzi, L. Smith, 2022, Frontiers in Neurology.

Complex I, Iron, and ferritin in Parkinson's disease substantia nigra

C. Marsden, J. Cooper, A. Schapira, 1994, Annals of neurology.

Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model

J. Taanman, M. Gegg, A. Schapira, 2022, Human molecular genetics.

Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement

J. Cooper, A. Schapira, A. Schapira, 1992, Journal of neurochemistry.

A cue to queue for CoQ?

C. Shults, A. Schapira, 2001, Neurology.

Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells

J. Cooper, J. Taanman, M. Gegg, 2009, PloS one.

Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129

J. Cooper, K. Chau, A. Schapira, 2013, Journal of Molecular Neuroscience.

G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage

S. Tabrizi, J. Cooper, M. Orth, 2004, Neurochemistry International.

Polypeptide and glycoprotein abnormalities in dorsal root ganglia of streptozotocin-diabetic rats

A. Schapira, P. Thomas, A. Schapira, 1989, Journal of the Neurological Sciences.

Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide

S. Moncada, V. Darley-Usmar, A. Schapira, 1994, FEBS letters.

Analysis of mutant DNA polymerase γ in patients with mitochondrial DNA depletion

A. Pagnamenta, M. Bitner-Glindzicz, S. Rahman, 2009, Human mutation.

Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)

C. Davie, M. Daras, J. Muddle, 2009, Neuromuscular Disorders.

Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy

J. Cooper, J. Bradley, A. Schapira, 2008, European journal of neurology.

Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene

P. Jarman, K. Bhatia, E. Valente, 2002, Movement disorders : official journal of the Movement Disorder Society.

Mitochondria: Aspects for neuroprotection

A. Schapira, P. Hart, 1999 .

Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA

J. Cooper, A. Harding, A. Toscano, 1989, Annals of neurology.

Biochemical abnormalities and excitotoxicity in Huntington's disease brain

S. Tabrizi, J. Cooper, J. Taanman, 1999, Annals of neurology.

Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: Effect of ageing

J. Cooper, A. Schapira, V. Mann, 1992, Journal of the Neurological Sciences.

Friedreich's Ataxia: Disease mechanisms, antioxidant and Coenzyme Q10 therapy

J. Cooper, A. Schapira, 2003, BioFactors.

Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia

C. Marsden, A. Schapira, D. Dexter, 1992 .

Platelet aggregation in myotonia

A. Schapira, R. Hutton, 1985, Journal of the Neurological Sciences.

International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study

Paolo Barone, Graeme MacPhee, Fabrizio Stocchi, 2006, Movement disorders : official journal of the Movement Disorder Society.

Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins

J. Cooper, A. Schapira, Tracey A Seaton, 1998, Brain Research.

Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice

J. Cooper, M. Wood, S. El-Andaloussi, 2014, Movement disorders : official journal of the Movement Disorder Society.

Platelet mitochondrial function in Leber's hereditary optic neuropathy

J. Cooper, A. Schapira, A. Harding, 1994, Journal of the Neurological Sciences.

Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia

A. Blamire, J. Francis, S. Neubauer, 2010, Movement disorders : official journal of the Movement Disorder Society.

Mitochondrial defect in Huntington's disease caudate nucleus

J. Cooper, F. Javoy‐Agid, A. Schapira, 1996, Annals of neurology.

Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism

T. Gasser, K. Brockmann, C. Ugalde, 2023, Nature Communications.

Clinical correlates of mitochondrial function in Huntington's disease muscle

J. Cooper, A. Schapira, C. Turner, 2007, Movement disorders : official journal of the Movement Disorder Society.

MOLECULAR BASIS OF MITOCHONDRIAL MYOPATHIES: POLYPEPTIDE ANALYSIS IN COMPLEX-1 DEFICIENCY

J. Cooper, C. Ragan, A. Schapira, 1988, The Lancet.

Molecular defects of NADH-ubiquinone oxidoreductase (Complex I) in mitochondrial diseases

J. Cooper, A. Schapira, J. Morgan-Hughes, 1988, Journal of bioenergetics and biomembranes.

Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal

A. Schapira, A. H. V. Schapira, 2004, Movement disorders : official journal of the Movement Disorder Society.

Platelet mitochondria function in Parkinson's disease

Anthony H.V. Schapira, C. Marsden, J. Cooper, 1992 .

Mitochondrial function in Parkinson's disease

C. Marsden, J. Cooper, D. Krige, 1992, Annals of neurology.

Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse

A H Schapira, S. Tabrizi, J. Cooper, 2000, Annals of neurology.

Mitochondria in the etiology and pathogenesis of parkinson's disease

S. Tabrizi, A. Schapira, J. Cooper, 1998, Annals of neurology.

Central role and mechanisms of β‐cell dysfunction and death in friedreich ataxia–associated diabetes

A. Koeppen, C. Depondt, M. Pandolfo, 2012, Annals of neurology.

Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases

C. Marsden, J. Cooper, D. Dexter, 1998, Journal of the Neurological Sciences.

Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy

A. Schapira, Philip Campbell, M. Toffoli, 2020, Movement disorders : official journal of the Movement Disorder Society.

Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes?

J. Hobart, J. Cooper, S. Cano, 2006, Movement disorders : official journal of the Movement Disorder Society.

In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by 31P magnetic resonance spectroscopy

G. Radda, S. Tabrizi, P. Styles, 1997, Annals of neurology.

Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease

J. Cooper, J. Taanman, A. Schapira, 1998, Annals of neurology.

Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia

A H Schapira, A. Blamire, D. Manners, 2001, Annals of neurology.

L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain

C. Marsden, J. Cooper, A. Schapira, 1995, Movement disorders : official journal of the Movement Disorder Society.

Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease

W. Poewe, O. Rascol, R. Hauser, 2010, Movement disorders : official journal of the Movement Disorder Society.

Mitochondrial DNA mutation underlying Leigh's syndrome: Clinical, pathological, biochemical, and genetic studies of a patient presenting with progressive myoclonic epilepsy

C. R. Kennedy, J. Cooper, A. Harding, 1994, Journal of the Neurological Sciences.

Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease

J. Cooper, A. Schapira, A. Schapira, 1993, Brain Research.

International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia?

J. Hobart, J. Cooper, S. Cano, 2005, Movement disorders : official journal of the Movement Disorder Society.

Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing

Simon C. Potter, Miguel Ángel Martínez, C. Spencer, 2017, Genome Biology.

Friedreich's ataxia impact scale: A new measure striving to provide the flexibility required by today's studies

J. Hobart, J. Cooper, S. Cano, 2009, Movement disorders : official journal of the Movement Disorder Society.

α-Synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone

A. H. V. Schapira, J. M. Cooper, S. Tabrizi, 2003, Neuroscience Letters.

Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons

J. Cooper, J. Muddle, A. Schapira, 2006, Annals of neurology.

Mitochondrial function in Alzheimer's disease

J. Cooper, A. Schapira, A. Schapira, 1993, The Lancet.

Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology

R. King, J. Taanman, M. Gegg, 2009, Experimental Neurology.

MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE

A. H. V. Schapira, J. M. Cooper, D. Dexter, 1989, The Lancet.

Mitochondrial DNA analysis in Parkinson's disease

A. Schapira, A. Harding, A. Schapira, 1990, Movement disorders : official journal of the Movement Disorder Society.

Nitric oxide enhances MPP+ inhibition of complex I

J. Cooper, A. Schapira, M. Cleeter, 2001, FEBS letters.

Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors.

A H Schapira, J. Cooper, A. Schapira, 1997, Brain research.

Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease

A Hartley, A H Schapira, J. Cooper, 1994, Journal of neurochemistry.

Mitochondrial Complex I Deficiency in Parkinson's Disease

C. Marsden, J. Cooper, D. Dexter, 1990, Lancet.

Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion.

J. Cooper, A. Schapira, A. Bodnar, 1993, American journal of human genetics.

Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype.

J. Cooper, A. Schapira, A. Harding, 1995, Biochimica et biophysica acta.

Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia.

D. Manners, P. Styles, R. Lodi, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures.

J. Cooper, A. Schapira, J. Taanman, 1999, The American journal of pathology.

Liver failure associated with mitochondrial DNA depletion.

S. Love, J. Cooper, A. Schapira, 1998, Journal of hepatology.

Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy.

A. Schapira, J. Cooper, J. Taanman, 2010, Human molecular genetics.

PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy

A. Schapira, Heather L. Smith, K. Chau, 2016 .

Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia.

A. Schapira, A. Schapira, 1999, Biochimica et biophysica acta.

High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study

A. Blamire, S. Tabrizi, D. Manners, 2005, Neurology.

Mitochondrial dysfunction in neurodegenerative disorders.

A. Schapira, A. Schapira, 1998, Biochimica et biophysica acta.

Human complex I defects in neurodegenerative diseases.

A. Schapira, A. Schapira, A H Schapira, 1998, Biochimica et biophysica acta.

Cytochrome c oxidase deficiency associated with the first stop-codon point mutation in human mtDNA.

I. Nelson, N. Wood, S. Heales, 1998, American journal of human genetics.

Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease

J. Obeso, M. Rodriguez-Oroz, A. Schapira, 2013, Cell Death and Disease.

Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.

C. Marsden, J. Cooper, A. Schapira, 1992, Brain : a journal of neurology.

Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease

C. Marsden, J. Cooper, S. Daniel, 1990, Journal of neurochemistry.

Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains

J. Hardy, A. Schapira, N. Wood, 2012, Annals of neurology.

Anaesthetics increase light emission from aequorin at constant ionised calcium

P. F. Baker, A. Schapira, A. Schapira, 1980, Nature.

Mitochondria and degenerative disorders.

M. Orth, M. Orth, A. Schapira, 2001, American journal of medical genetics.

Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia.

J. Cooper, J. Bradley, A. Schapira, 2000, Human molecular genetics.

Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy.

A Seller, A H Schapira, S. Tabrizi, 1998, Brain : a journal of neurology.

A new family with paroxysmal exercise induced dystonia and migraine: a clinical and genetic study

N. Quinn, K. Bhatia, N. Wood, 2000, Journal of neurology, neurosurgery, and psychiatry.

Mitochondrial DNA in focal dystonia: A cybrid analysis

S. Tabrizi, J. Cooper, A. Schapira, 1998, Annals of neurology.

Mitochondrial function in neurodegeneration and ageing.

J. Cooper, A. Schapira, A. Schapira, 1992, Mutation research.

Oxidative stress and mitochondrial dysfunction in neurodegeneration

A. Schapira, A. Schapira, 1996, Current opinion in neurology.

G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization

M. Duchen, J. Cooper, A. Schapira, 2012, Human molecular genetics.

Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129

J. Cooper, K. Chau, A. Schapira, 2013, Journal of Molecular Neuroscience.

Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy

D. Manners, P. Styles, A. Schapira, 2000, Annals of neurology.

Bimodal administration of entacapone in Parkinson’s disease patients improves motor control

G. Meola, A. Schapira, S. Bareggi, 2008, European journal of neurology.

Mitochondrial respiratory chain function in multiple system atrophy

C. Marsden, N. Quinn, J. Cooper, 1997, Movement disorders : official journal of the Movement Disorder Society.

A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy.

I. Nelson, J. Cooper, A. Schapira, 1999, American journal of human genetics.

Mitochondria, free radicals, neurodegeneration and aging

A. Schapira, 1995 .

Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms

A. Schapira, J. Cooper, P. Jenner, 2005 .

Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group.

D. Dexter, A. Schapira, P. Jenner, 1992, Annals of neurology.

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

A. Blamire, D. Manners, P. Styles, 2005, Archives of neurology.

Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease

Simon C. Potter, Miguel Ángel Martínez, C. Spencer, 2017, Brain : a journal of neurology.

PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy

A. Schapira, Heather L. Smith, K. Chau, 2016, The Journal of cell biology.

Creatine therapy for Huntington’s disease: Clinical and MRS findings in a 1-year pilot study

A. Blamire, D. Manners, P. Styles, 2003, Neurology.

Mitochondrial dysfunction in neurodegenerative disorders.

A. Schapira, 1998, Biochimica et biophysica acta.

Molecular mechanisms in mitochondrial DNA depletion syndrome.

J. Cooper, A. Schapira, P. Clayton, 1997, Human molecular genetics.

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

J. Cooper, A. Schapira, K. Chau, 2010, Neurochemistry International.

Mitochondrial myopathy with a defect of mitochondrial-protein transport.

J. Cooper, A. Schapira, A. Schapira, 1990, The New England journal of medicine.

Friedreich's ataxia impact scale: A new measure striving to provide the flexibility required by today's studies

J. Hobart, J. Cooper, S. Cano, 2009, Movement disorders : official journal of the Movement Disorder Society.

Mitochondrial myopathies: clinical defects.

J. Cooper, A. Schapira, A. Harding, 1990, Biochemical Society transactions.

A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease

C. Marsden, G. Kemp, J. Cooper, 1994, Journal of the Neurological Sciences.

Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency.

J. Cooper, A. Schapira, A. Schapira, 2001, The Biochemical journal.

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Nir Giladi, T. Simuni, T. Gasser, 2023, The Lancet Neurology.